Financials GlaxoSmithKline Pharmaceuticals Limited

Stocks

GLAXO

INE159A01016

Pharmaceuticals

Market Closed - 09:59:29 17/11/2026 GMT 5-day change 1st Jan Change
2,674.45 INR +0.96% Intraday chart for GlaxoSmithKline Pharmaceuticals Limited -1.34% +8.24%

Projected Income Statement: GlaxoSmithKline Pharmaceuticals Limited

Forecast Balance Sheet: GlaxoSmithKline Pharmaceuticals Limited

Forecast Balance Sheet - GlaxoSmithKline Pharmaceuticals Limited
Fiscal Period: March 2022 2023 2024 2025 2026 2027 2028 2029
Net Debt -25,363 -16,656 - - - - - -
Change - 34.33% - - - - - -
Announcement Date 16/05/22 17/05/23 17/05/24 13/05/25 13/05/26 - - -
Estimates

Cash Flow Forecast: GlaxoSmithKline Pharmaceuticals Limited

Fiscal Period: March 2022 2023 2024 2025 2026 2027 2028 2029
CAPEX 1 346.4 440.4 312.2 230.2 552.8 583.3 583.3 625
Change - 27.14% -29.11% -26.27% 140.14% 5.52% 0% 7.14%
Free Cash Flow (FCF) 1 7,761 4,402 5,508 12,669 8,480 12,016 13,464 15,112
Change - -43.28% 25.12% 130.02% -33.06% 41.69% 12.06% 12.23%
Announcement Date 16/05/22 17/05/23 17/05/24 13/05/25 13/05/26 - - -
1INR in Million
Estimates

Forecast Financial Ratios: GlaxoSmithKline Pharmaceuticals Limited

Fiscal Period: March 2022 2023 2024 2025 2026 2027 2028 2029

Profitability

        
EBITDA Margin (%) 25.24% 24.73% 26.31% 31.4% 34.26% 34.24% 35.04% 35.03%
EBIT Margin (%) 23.16% 22.71% 24.29% 29.62% 32.52% 34.2% 35.05% 34.17%
EBT Margin (%) 23.77% 25.72% 23.63% 33.6% 36.79% 36.43% 37.14% 37.17%
Net margin (%) 51.7% 18.78% 17.08% 24.74% 27.11% 27.34% 27.66% 27.76%
FCF margin (%) 23.68% 13.54% 15.95% 33.79% 22.19% 27.73% 27.78% 28.52%
FCF / Net Income (%) 45.8% 72.08% 93.36% 136.58% 81.86% 101.4% 100.43% 102.75%

Profitability

        
ROA - - - - - - - -
ROE 81.85% 27.73% 33.53% 49.75% 49.11% 44.83% 42.32% 37.45%

Financial Health

        
Leverage (Debt/EBITDA) - - - - - - - -
Debt / Free cash flow - - - - - - - -

Capital Intensity

        
CAPEX / Current Assets (%) 1.06% 1.35% 0.9% 0.61% 1.45% 1.35% 1.2% 1.18%
CAPEX / EBITDA (%) 4.19% 5.48% 3.44% 1.96% 4.22% 3.93% 3.43% 3.37%
CAPEX / FCF (%) 4.46% 10% 5.67% 1.82% 6.52% 4.85% 4.33% 4.14%

Items per share

        
Cash flow per share 1 - - - - - - - -
Change - - - - - - - -
Dividend per Share 1 30 32 32 42 57 29.5 29.5 35
Change - 6.67% 0% 31.25% 35.71% -48.25% 0% 18.64%
Book Value Per Share 1 157.2 102.8 104.9 115.2 133.8 156 184.7 209.1
Change - -34.61% 2.1% 9.76% 16.19% 16.58% 18.37% 13.21%
EPS 1 100 36.05 34.83 54.76 61.15 69.37 79.15 86.8
Change - -63.96% -3.38% 57.22% 11.67% 13.44% 14.1% 9.67%
Nbr of stocks (in thousands) 169,406 169,406 169,406 169,406 169,406 169,406 169,406 169,406
Announcement Date 16/05/22 17/05/23 17/05/24 13/05/25 13/05/26 - - -
1INR
Estimates
2027 *2028 *
P/E 38.8x 34x
PBR 17.3x 14.6x
EV / Sales 10.5x 9.41x
Yield 1.1% 1.1%

EPS & Dividend

EPS & Dividend - GlaxoSmithKline Pharmaceuticals Limited


Y-o-Y evolution of P/E

Valuation ratios - P/E - GlaxoSmithKline Pharmaceuticals Limited
 

Year-on-year evolution of the Yield

Valuation ratios - Yield - GlaxoSmithKline Pharmaceuticals Limited
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - GlaxoSmithKline Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,649.00INR
Average target price
3,053.50INR
Spread / Average Target
+15.27%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GlaxoSmithKline Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. GLAXO Stock
  4. Financials GlaxoSmithKline Pharmaceuticals Limited